New drug tested for Tough-to-Treat skin cancer
NCT ID NCT06285370
Summary
This study is testing how well and how safe the drug mogamulizumab is for Chinese adults with advanced forms of a rare skin cancer called cutaneous T-cell lymphoma. The drug is given through an IV to people whose cancer has continued to grow despite at least one prior treatment. The main goal is to see if the treatment can shrink the cancer and for how long.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Zhengzhou University
Henan, Zhengzhou, 450052, China
-
Peking University First Hospital, Department of Dermatology and Venereology
Beijing, Beijing Municipality, 100034, China
-
Sun Yat-sen University Cancer Center, Department of Medical Oncology
Guangzhou, Guangdong, 510060, China
-
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, 010000, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110002, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610044, China
-
ZheJiang Cancer Hospital
Hangzhou, Zhejiang, 310005, China
Conditions
Explore the condition pages connected to this study.